Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Immune Checkpoint Bioassays Power Combination Immunotherapy

Here we present the following bioassays: 

  • Co-inhibitory Bioassays (PD-1, CTLA-4, LAG-3, TIGIT, CD226)
  • Co-stimulatory Bioassays (GITR, 4-1BB, OX40, CD40, HVEM)
  • Combination Bioassay (PD-1+TIGIT)
  • T Cell Activation Bioassays for bispecific antibodies and CAR-T
    cell immunotherapies

Summary

Therapeutic antibodies designed to block or activate immune checkpoint receptors are a powerful new approach to the treatment of cancer and other diseases. However, due to their biologic complexity the development of therapeutic antibodies requires unique functional and analytical tools. This webinar highlights the a suite of MOA-based functional bioassays for use in antibody screening, characterization, potency testing and stability studies.


Speaker

richard-somberg-125x126

Richard Somberg, PhD
Strategic Collaborations Manager
Promega Corporation

Richard is a Strategic Collaborations Manager focusing on building strategic relationships with biotech and pharmaceutical customers through technical introductions on early access technologies, custom assay services, and collaborative support. Prior to Promega, Dr. Somberg worked at Life Technologies where he led product development and service efforts in biochemical and cell-based assays for key target classes in drug discovery. He received his Ph.D. in immunology from Purdue University and completed post-doctoral studies at the University of Pennsylvania.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up